CheckRareTreatment Benefit of Daratumumab for Multiple Myeloma Supported by 3-Year Follow-Up Data

Jacob Laubach, MD, at the Dana-Farber Cancer Institute provides a summary of the most recent update from the GRIFFIN trial, assessing daratumumab plus lenalidomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma patients. After 24 months of maintenance therapy or treatment discontinuation (median follow-up of 38.6 months), the rate of stringent complete response (sCR) was […]

American Society of HematologyClonal Hematopoiesis in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Source: Blood AdvancesKey Points: In a cohort of 154 patients with NHL or MM receiving CAR T-cells, clonal hematopoiesis of indeterminate potential (CHIP) was present in 48%. Although associated with worse prognosis in these patients receiving autologous transplantation, no such association was seen in these patients receiving CAR T. Instead, the authors saw increased rates […]

American Society of Clinical OncologyWhat “The Princess Bride” Teaches Us About Outcomes in Multiple Myeloma

“It’s inconceivable!” This famous line and exchange from the 1987 classic film The Princess Bride, along with the fates of the characters Vizzini and Inigo Montoya, provide the fulcrum for this Journal of Clinical Oncology (JCO) editorial, which highlights the phase III TOURMALINE-MM1 trial and its seemingly “negative” findings in multiple myeloma (MM). Are we […]

Millennium Medical PublishingCurrent Antibody-Based Therapies for the Treatment of Multiple Myeloma

Published in Clinical Advances in Hematology & Oncology, this article presents an overview of the currently available monoclonal antibody treatments in multiple myeloma (MM), discussing  the clinical value, significant potential, and possible limitations of these immunotherapeutic approaches to driving deeper responses and achieving longer overall survival among patients with a challenging disease.